Safety update on erythropoiesis-stimulating agents: Trials within and outside the accepted indications

Oncologist

Volumn 13, Issue SUPPL. 3, 2008, Pages 4-10

  Gasćn, Pere ^a  

^a UNIVERSITY OF BARCELONA   (Spain)

Author keywords

Anemia; Erythropoiesis Stimulating agents; ESAs; Safety; Survival

Indexed keywords

EGYPO; NOVEL ERYTHROPOIESIS STIMULATING PROTEIN; PLACEBO; RECOMBINANT ERYTHROPOIETIN; UNCLASSIFIED DRUG; ANTIANEMIC AGENT; ANTINEOPLASTIC AGENT; HEMOGLOBIN;

ANEMIA; CANCER CHEMOTHERAPY; CANCER PATIENT; CLINICAL STUDY; DRUG SAFETY; HEMOGLOBIN BLOOD LEVEL; HUMAN; PRIORITY JOURNAL; REVIEW; SURVIVAL; TREATMENT INDICATION; TREATMENT OUTCOME; VENOUS THROMBOEMBOLISM; CHEMICALLY INDUCED DISORDER; CLINICAL TRIAL; DRUG APPROVAL; META ANALYSIS; MORTALITY; NEOPLASM;

ANEMIA; ANTINEOPLASTIC AGENTS; CLINICAL TRIALS AS TOPIC; DRUG APPROVAL; ERYTHROPOIETIN, RECOMBINANT; HEMATINICS; HEMOGLOBINS; HUMANS; META-ANALYSIS AS TOPIC; NEOPLASMS;

EID: 54049083072     PISSN: 10837159     EISSN: 1549490X     Source Type: Journal    
DOI: 10.1634/theoncologist.13-S3-4     Document Type: Review

References (50)

1. Ludwig H, Van Belle S, Barrett-Lee P et al. The European Cancer Anaemia Survey (ECAS): A large, multinational, prospective survey defining the prevalence, incidence, and treatment of anaemia in cancer patients. Eur J Cancer 2004;40:2293-2306.
2. Littlewood TJ, Bajetta E, Nortier JW et al. Effects of epoetin alfa on hematologic parameters and quality of life in cancer patients receiving non-platinum chemotherapy: Results of a randomized, double-blind, placebo-controlled trial. J Clin Oncol 2001;19:2865-2874.
3. Bohlius J, Wilson J, Seidenfeld J et al. Recombinant human erythropoietins and cancer patients: Updated meta-analysis of 57 studies including 9353 patients. J Natl Cancer Inst 2006;98:708-714.
4. Shasha D, George MJ, Harrison LB. Once weekly dosing of epoetin-alpha increases hemoglobin and improves quality of life in anemic cancer patients receiving radiation therapy either concomitantly or sequentially with chemotherapy. Cancer 2003;98:1072-1079.
5. Henke M, Laszig R, Rube C et al. Erythropoietin to treat head and neck cancer patients with anaemia undergoing radiotherapy: Randomised, double-blind, placebo-controlled trial. Lancet 2003;362:1255-1260.
6. Henke M, Mattern D, Pepe M et al. Do erythropoietin receptors on cancer cells explain unexpected clinical findings? J Clin Oncol 2006;24:4708-4713.
7. Leyland-Jones B, Semiglazov V, Pawlicki M et al. Maintaining normal hemoglobin levels with epoetin alfa in mainly nonanemic patients with metastatic breast cancer receiving first-line chemotherapy: A survival study. J Clin Oncol 2005;23:5960-5972.
8. Randal J. FDA panel scrutinizes safety of anti-anemia drugs. J Natl Cancer Inst 2004;96:1061; doi: 10.1093/jnci/96.14.1061.
9. U.S. Food and Drug Administration. Oncologic Drugs Advisory Committee. May 4, 2004. Slides. Available at http://www.fda.gov/ohrms/dockets/ac/04/slides/ 4037s2.htm. Accessed March 3, 2008.
10. U.S. Food and Drug Administration. Oncologic Drugs Advisory Committee. May 4, 2004. Briefing Information. Available at http://www.fda.gov/ ohrms/dockets/ac/04/briefing/4037b2.htm. Accessed March 3, 2008.
11. Bohlius J, Wilson J, Seidenfeld J et al. Erythropoietin or darbepoetin for patients with cancer. Cochrane Database Syst Rev 2006;3:CD003407.
12. Rose E, Rai K, Revicki D et al. Clinical and health status assessments in anemic chronic lymphocytic leukemia (CLL) patients treated with epoetin alfa (EPO). Blood 1994;84(suppl 1):526a.
13. Hearings before the Subcommittee on Oncologic Drugs Advisory Committee of the House Committee on Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and Research. P-174. May 4, 2004. Available at http://www.fda.gov/cder/ drug/infopage/RHE/default.htm.
14. Case DC Jr, Bukowski RM, Carey RW et al. Recombinant human erythropoietin therapy for anemic cancer patients on combination chemotherapy. J Natl Cancer Inst 1993;85:801-806.
15. Henry DH, Brooks BJ Jr, Case DC Jr et al. Recombinant human erythropoietin therapy for anemic cancer patients receiving cisplatin chemotherapy. Cancer J Sci Am 1995;1:252-260.
16. Hearings Before the Subcommittee on Oncologic Drugs Advisory Committee of the House Committee on Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and Research, INT-1, May 4, 2004. Available at http://www.fda.gov/cder/ drug/infopage/RHE/default.htm.
17. Dammacco F, Castoldi G, Rǒdjer S. Efficacy of epoetin alfa in the treatment of anaemia of multiple myeloma. Br J Haematol 2001;113:172-179.
18. Hearings Before the Subcommittee on Oncologic Drugs Advisory Committee of the House Committee on Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and Research, INT-3, May 4, 2004. Available at http://www.fda.gov/cder/ drug/infopage/RHE/default.htm.
19. Witzig TE, Silberstein PT, Loprinzi CL et al. Phase III, randomized, double-blind study of epoetin alfa compared with placebo in anemic patients receiving chemotherapy. J Clin Oncol 2005;23:2606-2617.
20. Hearings Before the Subcommittee on Oncologic Drugs Advisory Committee of the House Committee on Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and Research, N93 004. May 4, 2004. Available at http://www.fda.gov/cder/ drug/infopage/RHE/default.htm.
21. Leyland-Jones B; BEST Investigators and Study Group. Breast cancer trial with erythropoietin terminated unexpectedly. Lancet Oncol 2003;4:459-460.
22. Vansteenkiste J, Pirker R, Massuti B et al. Double-blind, placebo-controlled, randomized phase III trial of darbepoetin alfa in lung cancer patients receiving chemotherapy. J Natl Cancer Inst 2002;94:1211-1220.
23. Oberhoff C, Neri B, Amadori D et al. Recombinant human erythropoietin in the treatment of chemotherapy-induced anemia and prevention of transfusion requirement associated with solid tumors: A randomized, controlled study. Ann Oncol 1998:9:255-260.
24. Blohmer JU, Wurschmidt F, Petry U et al. Results with sequential adjuvant chemo-radiotherapy with vs. without epoetin alfa for patients with high-risk cervical cancer: Results of a prospective, randomized, open and controlled AGO- and NOGGO-intergroup study. Ann Oncol 2004; 15(suppl 3):477.
25. Taylor K, Ganly P, Cham V. Randomized, double-blind, placebo-controlled study of darbepoetin alfa every 3 weeks for the treatment of chemotherapy-induced anemia. Blood 2005; 106:Abstract 3556.
26. Chang J, Couture F, Young S et al. Weekly epoetin alfa maintains hemoglobin, improves quality of life, and reduces transfusion in breast cancer patients receiving chemotherapy. J Clin Oncol 2005;23:2597-2605.
27. Osterborg A, Brandberg Y, Hedenus M. Impact of epoetin-beta on survival of patients with lymphoproliferative malignancies: Long-term follow up of a large randomized study. Br J Haematol 2005;129:206-209.
28. Savonije J, Van Groeningen C, Van Bochove A et al. Effects of early intervention with epoetin-alfa on transfusion requirement, hemoglobin level and survival during platinum-based chemotherapy: Results of a multi-center randomised controlled trial. Eur J Cancer 2005;41:1560-1569.
29. Pronzato P, Cortesi E, van der Rijt C et al. Early intervention with epoetin alfa in breast cancer (BC) patients (pts) undergoing chemotherapy (CT): Results of a randomized, multicenter. phase 111b study (EPO-INT-47 Study Group). Ann Oncol 2002:13(suppl5):168.
30. Hedenus M, Adriansson M, San Miguel J et al. Efficacy and safety of darbepoetin alfa in anaemic patients with lymphoproliferative malignancies: A randomized, double-blind, placebo-controlled study. Br J Haematol 2003;122:394-403.
31. Kotasek D, Steger G. Faught W et al. Darbepoetin alfa administered every 3 weeks alleviates anaemia in patients with solid tumours receiving chemotherapy: Results of a double-blind, placebo-controlled, randomised study. Eur J Cancer2003;39:2026-2034.
32. Osterborg A, Boogaerts MA, Cimino R et al. Recombinant human erythropoietin in transfusion-dependent anemic patients with multiple myeloma and non-Hodgkin's lymphoma-a randomized multicenter study. The European Study Group of Erythropoietin (Epoetin Beta) Treatment in Multiple Myeloma and Non-Hodgkin's Lymphoma. Blood 1996;87:2675-2682.
33. Coiffier B, Boogaerts M, Kainz C. Impact of epoetin beta versus standard care on quality of life in patients with malignant disease. Presented at the Sixth Congress of the European Haematology Association, Frankfurt, Germany, June21-24, 2001.
34. Grote T, Yeilding AL, Castillo R et al. Efficacy and safety analysis of epoetin alfa in patients with small-cell lung cancer: A randomized, double-blind, placebo-controlled trial. J Clin Oncol 2005;23:9377-9386.
35. ten Bokkel Huinink WW. de Swart CA, van Toorn DW et al. Controlled multicentre study of the influence of subcutaneous recombinant human erythropoietin on anaemia and transfusion dependency in patients with ovarian carcinoma treated with platinum-based chemotherapy. Med Oncol 1998;15:174-182.
36. Thatcher N. De Campos ES, Bell DR et al. Epoetin alpha prevents anaemia and reduces transfusion requirements in patients undergoing primarily platinum-based chemotherapy for small cell lung cancer. Br J Cancer 1999;80:396-402.
37. Cazzola M, Messinger D, Battistel V et al. Recombinant human erythropoietin in the anemia associated with multiple myeloma or non-Hodgkin's lymphoma: Dose finding and identification of predictors of response. Blood 1995;86:4446-4453.
38. Wilkinson PM, Antonopoulos M, Lahousen M et al. Epoetin alfa in platinum-treated ovarian cancer patients: Results of a multinational, multicentre, randomised trial. Br J Cancer 2006;94:947-954.
39. Aapro M, Barnadas A, Leonard RC et al. Effects of epoetin beta treatment in patients with metastatic breast cancer receiving chemotherapy. Results of the BRAVE trial. Presented at the 29th San Antonio Breast Cancer Symposium 2006, San Antonio, Texas, December 14-16, 2006. Available at: http://www. abstracts2view.com/sabcsO6/search. php?search=do&int MaxHits= 10&where%5B%5D=&andornot%5B%5D=&query=aapro. Accessed March 3.2008.
40. Moebus V, Lueck H, Thomssen C et al. The impact of epoetin-alpha on anemia, red blood cell (RBC) transfusions, and survival in breast cancer patients (pts) treated with dose-dense sequential chemotherapy: Mature results of an AGO phase III study (ETC trial). J Clin Oncol 2007:25(18 suppl):20s.
41. Hearings Before the Subcommittee on Oncologic Drugs Advisory Committee of the House Committee on Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and Research, EPO GBR-07; 2004. Available at http://www.fda.gov/cder/ drug/infopage/RHE/default.htm.
42. Del Mastro L, Venturini M, Lionetto R et al. Randomized phase III trial evaluating the role of erythropoietin in the prevention of chemotherapy-induced anemia. J Clin Oncol 1997;15:2715-2721.
43. Bamias A, Aravantinos G, Kalofonos C et al. Prevention of anemia in patients with solid tumors receiving platinum-based chemotherapy by recombinant human erythropoietin (rHuEpo): A prospective, open label, randomized trial by the Hellenic Cooperative Oncology Group. Oncology 2003;64:102-110.
44. Dunphy FR, Harrison BR, Dunleavy TL et al. Erythropoietin reduces anemia and transfusions: A randomized trial with or without erythropoietin during chemotherapy. Cancer 1999;86:1362-1367.
45. Razzouk BI, Hockenberry M, Hinds PS et al. A double-blind, placebo-controlled study of once-weekly epoetin alfa in children with cancer undergoing myelosuppressive chemotherapy. J Clin Oncol 2004:22(14 suppl):8527.
46. O'Shaughnessy J, Vukelja SJ, Holmes FA et al. Feasibility of quantifying the effects of epoetin alfa therapy on cognitive function in women with breast cancer undergoing adjuvant or neoadjuvant chemotherapy. Clin Breast Cancer 2005;5:439-446.
47. Amgen Inc. Background Information for Oncologic Drug Advisory Committee meeting, May 10, 2007. Safety of Erythropoiesis-Stimulating Agents (ESAs) in Oncology. Submitted April 7, 2007 by Amgen Inc., Thousand Oaks, C A.
48. Wright JR. Ung YC, Julian JA et al. Randomized, double-blind, placebo-controlled trial of erythropoietin in non-small-cell lung cancer with disease-related anemia. J Clin Oncol 2007;25:1027-1032.
49. Cascinu S, Fedeli A, Del Ferro E et al. Recombinant human erythropoietin treatment in cisplatin-associated anemia: A randomized, double-blind trial with placebo. J Clin Oncol 1994;12:1058-1062.
50. Kurz C. Marth C, Windbichler G et al. Erythropoietin treatment under polychemotherapy in patients with gynecologic malignancies: A prospective, randomized, double-blind placebo-controlled multicenter study. Gynecol Oncol 1997;65:461-466.